

Human VIPR2 Protein

Cat. No. VPR-HM302



Description

Source	Recombinant Human VIPR2 Protein is expressed from HEK293 with mFc tag at the C-terminus. It contains Glu24-Val126.
Accession	P41587-1
Molecular Weight	The protein has a predicted MW of 37.35 kDa. Due to glycosylation, the protein migrates to 45-60 kDa based on Tris-Bis PAGE result.
Endotoxin	Less than 1EU per µg by the LAL method.
Purity	> 95% as determined by Tris-Bis PAGE > 95% as determined by HPLC

Formulation and Storage


Formulation	Lyophilized from 0.22 µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage	-20 to -80°C for 12 months as supplied from date of receipt. -20 to -80°C for 3-6 months in unopened state after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

Effects of vasoactive intestinal peptide (VIP) on T cell migration are mediated by structurally distinct types I (VIPR1) and II (VIPR2) G protein-associated receptors. The two receptor types were proposed to transduce opposite effects on human T cells, since cytokine-induced chemotaxis of VIPR1-bearing HuT 78 human T cells, in contrast to T cells that express VIPR2, was inhibited by VIP.


Assay Data

Tris-Bis PAGE



Human VIPR2 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC



The purity of Human VIPR2 is greater than 95% as determined by SEC-HPLC.